Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2010-01, Vol.67 (1), p.86-92
• Main Authors: Gridelli, Cesare, Morabito, Alessandro, Gebbia, Vittorio, Mencoboni, Manlio, Carrozza, Francesco, Viganò, Maria Grazia, Verusio, Claudio, Bollina, Roberto, Mattioli, Rodolfo, Valerio, Maria Rosaria, Valmadre, Giuseppe, Maione, Paolo, Rossi, Antonio, Cascone, Tina, Morgillo, Floriana, Di Maio, Massimo, Piccirillo, Maria Carmela, Gallo, Ciro, Perrone, Francesco, Ciardiello, Fortunato
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Cetuximab; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Elderly patients; Female; Gemcitabine; Hematology, Oncology and Palliative Medicine; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Male; Medical sciences; Middle Aged; NSCLC; Patient Compliance; Pneumology; PS2 patients; Pulmonary/Respiratory; Treatment Outcome; Tumors; Tumors of the respiratory system and mediastinum; Young Adult
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2009.03.021

Abstract Background Two parallel randomized phase 2 trials were performed to choose the optimal way of combining cetuximab with gemcitabine in the first-line treatment of elderly (CALC1-E) and adult PS2 (CALC1-PS2) patients with advanced NSCLC. Methods Stage IV or IIIB NSCLC patients, aged ≥70 years with PS 0–2 for CALC1-E or aged